MED30 and gastric cancer: Knockdown of MED30 inhibited the proliferations of all gastric cancer cells tested (SNU16, SNU216, SNU620, and SNU638) versus SCR by 18%, 68%, 98%, and 42%, respectively (Fig 2D).